News & Updates

A robust association exists between increased natriuresis and successful decongestion with acetazolamide in patients with acute decompensated heart failure (ADHF), suggests a study.

Patients with Takotsubo syndrome (TTS), a reversible form of heart failure with incompletely understood pathophysiology, may exhibit reduced cardiac contractility, shortened systolic period, inefficient energetics, and prolonged active relaxation but unaffected diastolic passive stiffness, a study has shown.

Individuals born large for gestational age (LGA) are more likely to develop obesity and metabolic syndrome later in life than those born appropriate for gestational age, suggests a study.

Low-dose drug combinations that incorporate between three and four blood pressure (BP)-lowering medications appear to be well tolerated and effective for the initial or early management of hypertension, according to the results of a systematic review and meta-analysis.

The use of rivaroxaban in nonhospitalized patients with symptomatic COVID-19 falls short of reducing the composite endpoint of venous and arterial thrombotic events, hospitalization, and death, according to data from PREVENT-HD*.

Poor outcomes hound several patients with chronic kidney disease (CKD) who develop intracerebral haemorrhage, reveals a study presented at the recent AAN 2023.

Women with heart disease are at increased risk of developing hypertension in the decades after pregnancy compared with those without heart disease, as reported in a retrospective study.

A meta-analysis of randomized trials has revealed that influenza vaccination is effective at preventing all-cause mortality, cardiovascular mortality, major acute cardiovascular events, and acute coronary syndrome (ACS) among patients with coronary artery disease (CAD), particularly in those with ACS.

Use of any beta-blocker dose results in a significant decrease in mortality following acute myocardial infarction (AMI) when compared with no treatment, reports a study. Doses >25 percent to 50 percent of the currently recommended target dose (RTD) are associated with highest mortality reduction within the first year after AMI, indicating that higher doses are not required.